Cargando…
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial
The proteasome inhibitor bortezomib enhances the effect of the selective estrogen receptor (ER) downregulator (SERD) fulvestrant by causing accumulation of cytoplasmic ER aggregates in preclinical models. The purpose of this trial was to determine whether bortezomib enhanced the effectiveness of ful...
Autores principales: | Adelson, Kerin, Ramaswamy, Bhuvaneswari, Sparano, Joseph A, Christos, Paul J, Wright, John J, Raptis, George, Han, Gang, Villalona-Calero, Miguel, Ma, Cynthia X, Hershman, Dawn, Baar, Joseph, Klein, Paula, Cigler, Tessa, Budd, G Thomas, Novik, Yelena, Tan, Antoinette R, Tannenbaum, Susan, Goel, Anupama, Levine, Ellis, Shapiro, Charles L, Andreopoulou, Eleni, Naughton, Michael, Kalinsky, Kevin, Waxman, Sam, Germain, Doris |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515340/ https://www.ncbi.nlm.nih.gov/pubmed/28721390 http://dx.doi.org/10.1038/npjbcancer.2016.37 |
Ejemplares similares
-
Phase I/II Trial of Ruxolitinib in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer
por: Kearney, Matthew, et al.
Publicado: (2021) -
Predictors of Pain Reduction in Trials of Interventions for Aromatase Inhibitor–Associated Musculoskeletal Symptoms
por: Henry, N Lynn, et al.
Publicado: (2021) -
Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant
por: Kümler, Iben, et al.
Publicado: (2016) -
Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden
por: Sabale, Ugne, et al.
Publicado: (2017) -
Rethinking the combination treatment of fulvestrant and anastrozole for metastatic breast cancer: an integrated reanalysis of aromatase–estrogen receptor axis
por: Huang, Xing
Publicado: (2019)